Transl Clin Pharmacol.  2014 Jun;22(1):30-34.

Genetic Polymorphisms of the Carboxylesterase 1 (CES1) Gene in a Korean Population

• Cha YJ
• Jeong HE
• Shin JG
• Kim EY
• Yu KS
• Cho JY
• Yoon SH
• Lim KS

Abstract

Human carboxylesterase 1 (CES1) is a serine esterase that hydrolyzes various exogenous compounds. Single nucleotide polymorphisms (SNPs) of CES1 may lead to inter-individual metabolic variability of its substrates. The allele and haplotype frequencies of known SNPs have been demonstrated to vary among ethnic groups. We analyzed genetic variations of CES1 in a Korean population. Direct sequencing of all exons and flanking regions of the CES1 gene was performed on samples obtained from 200 Koreans. We identified 41 SNPs. The most frequent SNPs was -914G>C (frequency: 99.5%), followed by 4256G>A (frequency: 65.8%), -75T>G (frequency: 59.3%). Haplotype analysis using the identified SNPs revealed fifteen haplotypes (> or =1% haplotype frequency) in our samples. The most frequent haplotype was Hap1 (frequency: 15.4%). Among the identified 41 SNPs, nine of which are novel variants and 14 SNPs were nonsynonymous variants. Using the functional predictive software PolyPhen-2, the G19V, E221G, and A270S variants were predicted to be most likely damaging to the function and structure of CES1. In-vitro analyses for two of these variants have been previously performed; however, functional evaluation of E221G (11657A>G, rs200707504) still needs to be conducted. Therefore, further studies are warranted to characterize the functional impact of E221G on CES1 activity.

Keyword

Carboxylesterase 1; Sequencing; Single nucleotide polymorphism; Koreans

MeSH Terms

Alleles
Asian Continental Ancestry Group
Carboxylesterase*
Ethnic Groups
Exons
Genetic Variation
Haplotypes
Humans
Polymorphism, Genetic*
Polymorphism, Single Nucleotide
Serine
Carboxylesterase
Serine

Reference

References

1. Kim SR, Nakamura T, Saito Y, Sai K, Nakajima T, Saito H, et al. Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). Drug Metab Pharmacokinet. 2003; 18:327–332.

2. Walter Soria N, Belaus A, Galván C, Ana Pasquali M, Velez P, Del Carmen Montes C, et al. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. Genet Test Mol Biomarkers. 2010; 14:749–751.

3. Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, et al. The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. Eur J Clin Pharmacol. 2013; 69:21–30.

4. Staudinger JL1. Xu C, Cui YJ, Klaassen CD. Nuclear receptormediated regulation of carboxylesterase expression and activity. Expert Opin Drug Metab Toxicol. 2010; 6:261–271.

5. Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, ea al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics. 2004; 84:661–668.

6. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos. 2002; 30:488–493.

7. Redinbo MR, Bencharit S, Potter PM. Human carboxylesterase 1: from drug metabolism to drug discovery. Biochem Soc Trans. 2003; 31:620–624.

8. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008; 82:1241–1248.

9. Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2009; 37:264–267.

10. Bruxel EM, Salatino-Oliveira A, Genro JP, Zeni CP, Polanczyk GV, Chazan R, et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J. 2013; 13:476–480.

11. Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM, et al. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J. 2010; 10:524–536.

12. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7:248–249.

13. Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet. 2001; 10:591–597.

14. Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res. 2005; 28:719–725.

15. Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013; 344:665–672.

16. Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther. 2012; 92:68–71.

17. Ding XL, Deng YL, Zhang J, Miao LY. Mutation-sensitive molecular switch method to detect CES1A2 mutation in the Chinese Han and Yao populations. Genet Test Mol Biomarkers. 2011; 15:659–662.